Table 4.
Hazard ratios of SUA levels for incidence hypertension during 6 years of follow-up among 3591subjects without hypertension at the entyry examination
| Model | N (%) | Hazard ratio | 95 % CI | P-value |
|---|---|---|---|---|
| Baseline values: models 1–3 | ||||
| Model 1: unadjusted baseline values of variables | ||||
| Quartile 1 | 903 (25.1 %) | – | – | 0.000 |
| Quartile 2 | 886 (24.7 %) | 1.652 | 1.265–2.156 | 0.000 |
| Quartile 3 | 905 (25.2 %) | 2.195 | 1.705–2.825 | 0.000 |
| Quartile 4 | 897 (25.0 %) | 3.058 | 2.399–3.899 | 0.000 |
| SUA as a continuous variable (μmol/L) | 3591 | 2.039 | 1.747–2.379 | 0.000 |
| Model 2: model 1 adjusted for age and gender | ||||
| Quartile 1 | – | – | – | 0.000 |
| Quartile 2 | – | 1.644 | 1.253–2.158 | 0.000 |
| Quartile 3 | – | 2.274 | 1.746–2.963 | 0.000 |
| Quartile 4 | – | 3.174 | 2.448–4.114 | 0.000 |
| SUA as a continuous variable (μmol/L) | – | 1.703 | 1.292–2.243 | 0.000 |
| Model 3: model 2 further adjusted for other confounders | ||||
| Quartile 1 | – | – | – | 0.000 |
| Quartile 2 | – | 1.754 | 1.321–2.328 | 0.000 |
| Quartile 3 | – | 2.349 | 1.774–3.111 | 0.000 |
| Quartile 4 | – | 3.152 | 2.371–4.191 | 0.000 |
| SUA as a continuous variable (μmol/L) | – | 1.793 | 1.512–2.126 | 0.000 |
| Follow-up values: models 4–6 | ||||
| Model 4: unadjusted follow-up values of variables | ||||
| Quartile 1 | 897 (25.0 %) | – | – | 0.018 |
| Quartile 2 | 878 (24.5 %) | 1.279 | 1.029–1.590 | 0.027 |
| Quartile 3 | 917(25.5 %) | 1.160 | 0.886–1.519 | 0.281 |
| Quartile 4 | 899(25.0 %) | 1.366 | 1.120–1.666 | 0.002* |
| SUA as a continuous variable (μmol/L) | 3591 | 1.104 | 1.030–1.184 | 0.005* |
| Model 5: model 4 adjusted for age and sex | ||||
| Quartile 1 | – | – | – | 0.009* |
| Quartile 2 | – | 1.243 | 1.060–1.639 | 0.013* |
| Quartile 3 | – | 1.410 | 0.947–1.630 | 0.117 |
| Quartile 4 | – | 1.264 | 1.155–1.722 | 0.001* |
| SUA as a continuous variable (μmol/L) | – | 1.264 | 1.198–1.335 | 0.000 |
| Model 6: model 5 further adjusted for other confounders | ||||
| Quartile 1 | – | – | – | 0.026* |
| Quartile 2 | – | 1.103 | 1.031–1.179 | 0.004* |
| Quartile 3 | – | 1.043 | 0.778–1.398 | 0.780 |
| Quartile 4 | – | 1.350 | 1.106–1.648 | 0.003* |
| SUA as a continuous variable (μmol/L) | – | 1.157 | 1.066–1.255 | 0.001* |
Model 1–3 (Baseline) Quartiles based on serum uric acid levels: 1, <4.69 mg/dl; 2, 4.69–5.58 mg/dl; 3, 5.58–6.52 mg/dl; 4, ≥6.52 mg/dl
Model 4–6 (Means during follow-up period) Quartiles based on serum uric acid levels: 1, <4.64 mg/dl; 2, 4.64–5.41 mg/dl; 3, 5.41–5.78 mg/dl; 4, ≥5.78 mg/dl
Model 3 was further adjusted for BMI, triglycerides, eGFR, blood urea nitrogen, serum creatinine, plasma total protein, globulin, alanine aminotransferase, and direct bilirubin
Model 6 was further adjusted for BMI, triglycerides, total cholesterol, high-density lipoproteins, estimated glomerular filtration rate, blood urea nitrogen, serum creatinine, fasting plasma glucose, plasma total protein, globulin, albumin, alanine aminotransferase, total bilirubin, and direct bilirubin
* P < 0.05 was considered statistically significant